Conditions: Optic Neuritis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 44
Healthy volunteers: no

Brief summary:
The main objective of the study is to determine whether glatiramer acetate 20 mg once daily reduces the amount of axonal loss in the optic nerve after a first event of acute optic neuritis compared to placebo patients and to generate data supporting the potential neuroprotective effect of glatiramer acetate in a human in vivo model of axonal loss.

Detailed description:

Arms:
arm 1: Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months. arm 2: Participants received placebo subcutaneous injection once a day for up to 6 months.

Interventions: intervention 1: Glatiramer Acetate intervention 2: placebo
Intervention descriptions: intervention 1: 20 mg injected daily subcutaneously intervention 2: injected daily subcutaneously

Protocol document: